Skip to main content
. 2008 Sep 25;105(39):15040–15045. doi: 10.1073/pnas.0807055105

Fig. 4.

Fig. 4.

Improved antitumor efficacy of combined therapy with anti-VEGF antibody and tumstatin peptide. (A) The effect of combination antiangiogenic therapy in 786 human renal cell carcinoma. Tumor growth curves show the mean relative tumor volume ± SEM, n = 5–7. The tumor volume when treatment was started is normalized on the y axis. **, P < 0.02, compared with the control group. (B) The time for 786 human renal cell carcinomas to reach a tumor volume of 750 mm3. Bars depict the mean ± SEM, n = 5–7. **, P < 0.02, compared with the control group.